Michelle Glass

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 33

Top Venues

British journal of pharmacology

Forensic toxicology

ACS chemical neuroscience

ACS pharmacology & translational science

University of Otago

University of Auckland (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Otago Jul 24 2018

New Zealand

Head of Department :: Pharmacology and Toxicology

University of Auckland Oct 01 2000 - Jul 08 2018

New Zealand

Professor, Academic Director, School of Medical Sciences :: Department of Pharmacology and Clinical Pharmacology

Education History

University of Auckland

New Zealand

PHD :: Pharmacology

Publications

Hayley M Green, Jamie J Manning, Ian R Greig, Ruth A Ross, David B Finlay, Michelle Glass
Positive allosteric modulation of the cannabinoid CB 1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. British journal of pharmacology 181 (19) (2024)
Hayley M Green, Jamie J Manning, Ian R Greig, Ruth A Ross, David B Finlay, Michelle Glass
Positive allosteric modulation of the cannabinoid CB 1 receptor potentiates endocannabinoid signalling and changes ERK1/2 phosphorylation kinetics. British journal of pharmacology (2024)
Liang Yang, David B Finlay, Hayley M Green, Xiao Zhu, Michelle Glass, Stephen Duffull
A quantitative pharmacology model for cannabinoid receptor type 1 (CB 1 ) mediated by Gi/Gs protein competition. British journal of pharmacology (2023)
Liang Yang, Xiao Zhu, David B Finlay, Hayley Green, Michelle Glass, Stephen B Duffull
A kinetic model for positive allosteric modulator (PAM)-antagonists for the type 1 cannabinoid receptor (CB 1 ). British journal of pharmacology (2023)
Monica Patel, Natasha L Grimsey, Samuel D Banister, David B Finlay, Michelle Glass
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB 2 receptor. Pharmacology research & perspectives 11 (6) (2023)
Hunter D J Webb, David B Finlay, Shuli Chen, Andrea J Vernall, Eric Sparkes, Samuel D Banister, Rhonda J Rosengren, Michelle Glass
Characterisation of AMB-FUBINACA metabolism and CB 1 -mediated activity of its acid metabolite. Forensic toxicology 41 (1) (2022)
Jamie J Manning, Gabriel Rawcliffe, David B Finlay, Michelle Glass
Cannabinoid 1 (CB 1 ) receptor arrestin subtype-selectivity and phosphorylation dependence. British journal of pharmacology (2022)
Hunter D J Webb, David B Finlay, Shuli Chen, Andrea J Vernall, Eric Sparkes, Samuel D Banister, Rhonda J Rosengren, Michelle Glass
Characterisation of AMB-FUBINACA metabolism and CB 1 -mediated activity of its acid metabolite. Forensic toxicology 41 (1) (2022)
Hayley M Green, David B Finlay, Ruth A Ross, Iain R Greig, Stephen B Duffull, Michelle Glass
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1 H -indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator? ACS pharmacology & translational science 5 (12) (2022)
Hayley M Green, David B Finlay, Ruth A Ross, Iain R Greig, Stephen B Duffull, Michelle Glass
In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1 H -indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator? ACS pharmacology & translational science 5 (12) (2022)
Jack Markham, Eric Sparkes, Rochelle Boyd, Shuli Chen, Jamie J Manning, David B Finlay, Felcia Lai, Eila McGregor, Callan J Maloney, Roy R Gerona, Mark Connor, Iain S McGregor, David E Hibbs, Michelle Glass, Richard C Kevin, Samuel D Banister
Defining Steric Requirements at CB 1 and CB 2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS chemical neuroscience 13 (8) (2022)
Richard C Kevin, Somayeh Mirlohi, Jamie J Manning, Rochelle Boyd, Elizabeth A Cairns, Adam Ametovski, Felcia Lai, Jia Lin Luo, William T Jorgensen, Ross Ellison, Roy R Gerona, David E Hibbs, Iain S McGregor, Michelle Glass, Mark Connor, Chris Bladen, Gerald W. Zamponi, Samuel D Banister
Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca V 3) Inhibitors. ACS chemical neuroscience 13 (9) (2022)
Hunter D J Webb, David B Finlay, Shuli Chen, Andrea J Vernall, Eric Sparkes, Samuel D Banister, Rhonda J Rosengren, Michelle Glass
Characterisation of AMB-FUBINACA metabolism and CB 1 -mediated activity of its acid metabolite. Forensic toxicology 41 (1) (2022)
Ian Liddle, Michelle Glass, Joel D A Tyndall, Andrea J Vernall
Covalent cannabinoid receptor ligands - structural insight and selectivity challenges. RSC medicinal chemistry 13 (5) (2022)
Hunter D J Webb, David B Finlay, Shuli Chen, Andrea J Vernall, Eric Sparkes, Samuel D Banister, Rhonda J Rosengren, Michelle Glass
Characterisation of AMB-FUBINACA metabolism and CB 1 -mediated activity of its acid metabolite. Forensic toxicology 41 (1) (2022)
Hunter D J Webb, David B Finlay, Shuli Chen, Andrea J Vernall, Eric Sparkes, Samuel D Banister, Rhonda J Rosengren, Michelle Glass
Characterisation of AMB-FUBINACA metabolism and CB 1 -mediated activity of its acid metabolite. Forensic toxicology 41 (1) (2022)
Adam Ametovski, Elizabeth A Cairns, Katharina Elisabeth Grafinger, Annelies Cannaert, Marie H Deventer, Shuli Chen, Xinyi Wu, Caitlin E Shepperson, Felcia Lai, Ross Ellison, Roy Gerona, Karen Blakey, Richard C Kevin, Iain S McGregor, David E Hibbs, Michelle Glass, Christophe Pol Stove, Volker Auwärter, Samuel D Banister
NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? ACS chemical neuroscience 12 (21) (2021)
Monica Patel, Christoph Matti, Natasha L Grimsey, Daniel F Legler, Jonathan A Javitch, David B Finlay, Michelle Glass
Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β-arrestins and G protein-coupled receptor kinases. British journal of pharmacology (2021)
Liang Yang, Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
Exploring group size for statistical analysis of real-time signalling experiments. British journal of pharmacology 178 (19) (2021)
Thuy Nguyen, Thomas F Gamage, David B Finlay, Ann M Decker, Tiffany L Langston, Daniel Barrus, Michelle Glass, Jun-Xu Li, Terry P Kenakin, Yanan Zhang
Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. Journal of medicinal chemistry 65 (1) (2021)
Dimitri Daldegan-Bueno, Lucas Oliveira Maia, Michelle Glass, Didier Jutras-Aswad, Benedikt Fischer
Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. Psychopharmacology (2021)
David B Finlay, Stephen B Duffull, Michelle Glass
100 years of modelling ligand-receptor binding and response: A focus on GPCRs. British journal of pharmacology 177 (7) (2020)
Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. British journal of pharmacology 177 (15) (2020)
Adam Ametovski, Christa Macdonald, Jamie J Manning, S A Syed Haneef, Marina J Santiago, Lewis J Martin, Eric Sparkes, Andrew Reckers, Roy R Gerona, Mark Connor, Michelle Glass, Samuel D Banister
Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. ACS chemical neuroscience 11 (21) (2020)
Hunter Robson, Rhiannon Braund, Michelle Glass, Janelle Ashton, Michael Tatley
Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre. Clinical toxicology (Philadelphia, Pa.) 59 (6) (2020)
Samuel D Banister, Richard C Kevin, Lewis Martin, Axel Adams, Christa Macdonald, Jamie J Manning, Rochelle Boyd, Michael Cunningham, Marc Y Stevens, Iain S McGregor, Michelle Glass, Mark Connor, Roy R Gerona
The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. Drug testing and analysis 11 (7) (2019)
David B Finlay, Jamie J Manning, Mikkel Søes Ibsen, Christa E Macdonald, Monica Patel, Jonathan A Javitch, Samuel D Banister, Michelle Glass
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA. ACS chemical neuroscience 10 (10) (2019)
Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors. British journal of pharmacology 176 (14) (2019)
Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
An intact model for quantifying functional selectivity. Scientific reports 9 (1) (2019)
Samuel D Banister, Axel Adams, Richard C Kevin, Christa Macdonald, Michelle Glass, Rochelle Boyd, Mark Connor, Iain S McGregor, Christopher M Havel, Stephen J Bright, Mireia Ventura Vilamala, Cristina Gil Lladanosa, Monica J Barratt, Roy R Gerona
Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug testing and analysis 11 (2) (2018)
Anna G Cooper, Caitlin R M Oyagawa, Jamie J Manning, Sameek Singh, Sarah Hook, Natasha L Grimsey, Michelle Glass, Joel D A Tyndall, Andrea J Vernall
Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. MedChemComm 9 (12) (2018)
Xiao Zhu, David B Finlay, Michelle Glass, Stephen B Duffull
An evaluation of the operational model when applied to quantify functional selectivity. British journal of pharmacology 175 (10) (2018)
David B Finlay, Erin E Cawston, Natasha L Grimsey, Morag Rose Hunter, Anisha Korde, V Kiran Vemuri, Alexandros Makriyannis, Michelle Glass
Gαs signalling of the CB1 receptor and the influence of receptor number. British journal of pharmacology 174 (15) (2017)
William J Redmond, Erin E Cawston, Natasha L Grimsey, Jordyn Stuart, Amelia R Edington, Michelle Glass, Mark Connor
Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors. British journal of pharmacology 173 (1) (2015)

Michelle Glass.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Michelle Glass